The in vitro activities of lipsome-encapsulated amphotericin B and free amphotericin B against Candida albicans 336 were comparable. Amphotericin B concentrations 12-fold and greater than 50-fold higher were required to kill the same organism when cholesterol and ergosterol were incorporated into the liposomes. The addition of cholesterol to liposomes caused a significant increase in the minimal fungicidal concentration of amphotericin B in 7 of 19 other yeast strains tested, whereas ergosterol caused an increase in 18 of the 19 strains.
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Although there have been numerous reports on the use of liposome-encapsulated amphotericin B (L-AmpB) in the treatment of various infections in experimental animals (1, (4) (5) (6) 8) , this is the first report on the in vitro activity of LAmpB against various fungi. In the initial phase of this study, the lipid concentration of the liposomes was held constant with changing amphotericin B (AmpB) concentrations. However, later results showed that the minimal fungicidal concentrations (MFCs) were no different when both the L-AmpB and the lipid concentrations were serially diluted.
(These data were presented in part at the The formulation of L-AmpB has been previously described (5). Candida albicans 336, the strain used in the infected animal model (5), was grown overnight at 37°C on Sabouraud glucose agar plates. Cells were harvested by gently flushing the surfaces of the plates with sterile saline. The cells were washed two times, suspended in saline, and adjusted to 95% transmission of light (540 nm) with a Spectronic 20 (Bausch & Lomb, Inc., Rochester, N.Y.). Determination of antifungal susceptibility was performed by using the dilution methods described by Shadomy and Espinel-Ingroff (7). A 2-ml amount of buffered yeast-nitrogen base broth was used to serially dilute the various drug preparations. The concentrations of AmpB (free and liposomal) tested ranged from 0.05 to 50.0 ,g of AmpB per ml of broth. Tubes were inoculated with 50 RI of the cell inoculum.
Plate count studies indicated an initial colony count of 5 x 103 colonies per ml. MICs were not determined due to the turbidity of the liposomal preparations. The MFCs were determined after 18 h of incubation at 35°C. All tubes were subcultured (10 pul) onto Sabouraud glucose agar plates. The MFC was defined as the lowest concentration of drug that allowed no growth or fewer than four colonies on the subculture plates. Since the MICs could not be determined, the inhibitory effect of the lower concentrations of the drugs was determined after 18 h of incubation at 35°C. For these * Corresponding author. 387 data, 0.1 ml was removed from all drug concentrations tested. Serial dilutions (10-fold) were made, and 0.1 ml of each dilution (in duplicate) was plated onto Sabouraud glucose agar plates. Colony counts were made after 48 h of incubation by using the dilution plates that grew between 30 and 300 colonies per plate.
The results in Fig. 1 were the average of three experiments performed with three different L-AmpB preparations. Although these data were obtained with constant lipid (liposome) content, identical results were obtained if both the lipid and AmpB were diluted together (decreasing lipid content). Empty liposomes had no demonstrable inhibitory activity. As can be seen in the figure, the effect offree AmpB and the L-AmpB on the growth of C. albicans 336 was the same at all the drug concentrations tested. AmpB is incorporated into the lipid bilayer of the liposomes; therefore, we expected that the drug might be sequestered and not be as easily available to the fungal cell membrane as the free form of AmpB. Previous studies had shown that AmpB does not readily diffuse out of the liposomes in saline or in yeastnitrogen broth (2) . Therefore, the in vitro L-AmpB data imply that the drug is readily transferred from the liposomal membrane to the fungal membrane. Microscopic examination does not indicate that the liposomes attach or bind to the fungal cells; therefore, the mechanism of transfer of the drug is not clear. As also shown, empty liposomes added to free AmpB actually increased the antifungal activity of free AmpB at all concentrations below 0.8 pig/ml. These data are also difficult to explain. One possibility is that when AmpB is added to empty liposomes, the AmpB is concentrated in the outermost layers of the liposomes, thereby actually increasing the available drug concentrations to the fungal cell.
Other investigators have used liposomal preparations containing sterols (1, 6, 8) . AmpB binds to cholesterol present in mammalian cell membranes but has a much higher binding affinity for the ergosterol present in fungal membranes (3). We had previously found that AmpB is readily encapsulated into sterol-free and sterol-containing liposomes (2) . The in vitro antifungal activity against C. albicans 336 was then determined by using cholesterol-containing and ergosterolcontaining liposomal preparations (Fig. 1) . The cholesterol and ergosterol were incorporated into the liposomes at a ratio of 10:4 (phospholipid-sterol). As shown, the cholesterol-containing L-AmpB were somewhat more inhibitory at drug concentrations below 0.8 ,ug/ml; however, the MFC of C. albicans 336 was increased from 1.0 to 12 jig/ml with cholesterol-containing L-AmpB. The ergosterol-containing L-AmpB preparations were much less effective than any of the other drug preparations and had little demonstrable antifungal activity. The MFC was not achieved at the highest drug concentration tested. These data indicate that sterols, especially ergosterol, in the liposomes do effectively compete with the fungal cell for the drug.
Finally, we tested 19 other yeast strains representing five different genera in a similar manner (Table 1) . Only the MFC was determined in these latter studies. All drug concentrations tested were subcultured (10 ,ul) after 18 h of incubation, and the MFC was determined. Each isolate was tested on two different occasions. As can be seen, the MFC of LAmpB was significantly increased in only 4 of 19 isolates tested. Cholesterol-containing L-AmpB caused similar increases in 7 of 19 strains, whereas all strains, except a resistant Candida parasilosis (1341), showed an increased MFC when tested with ergosterol-containing L-AmpB. The four isolates with increased MFCs with L-AmpB are bothersome; however, the in vivo effect of L-AmpB on these organisms has not been determined. The dramatic in vitro effect of cholesterol and ergosterol on C. albicans 336 was not demonstrable when similar preparations were used to treat the infected mouse model (4 ergosterol in the liposomes reduces the effectiveness of the delivery system. Presumably, the ergosterol present in the liposomes competes for the AmpB, thereby decreasing availability of the drug to the fungal cell membrane. Further studies are needed to establish the mechanism(s) responsible for transfer of AmpB from liposomal to fungal membranes.
